BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37295817)

  • 21. Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells.
    Pietrovito L; Comito G; Parri M; Giannoni E; Chiarugi P; Taddei ML
    Curr Cancer Drug Targets; 2019; 19(10):807-816. PubMed ID: 30648509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells.
    Liu Y; Pan Y; Hu Z; Wu M; Wang C; Feng Z; Mao C; Tan Y; Liu Y; Chen L; Li M; Wang G; Yuan Z; Diao B; Wu Y; Chen Y
    Clin Infect Dis; 2020 Nov; 71(16):2150-2157. PubMed ID: 32442287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fusion of thymosin alpha 1 with mutant IgG1 CH3 prolongs half-life and enhances antitumor effects in vivo.
    Shen X; Wang L; Xu C; Yang J; Peng R; Hu X; Wang F; Zheng H; Lao X
    Int Immunopharmacol; 2019 Sep; 74():105662. PubMed ID: 31220695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
    de Groot AF; Blok EJ; Charehbili A; Engels CC; Smit VTHBM; Dekker-Ensink NG; Putter H; Meershoek-Klein Kranenbarg E; van de Velde CJH; Liefers GJ; Nortier JWR; Kuppen PJK; van der Burg SH; Kroep JR
    Breast Cancer Res Treat; 2019 Jun; 175(3):605-615. PubMed ID: 30868392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells.
    Liu H; Wang SH; Chen SC; Chen CY; Lin TM
    BMC Cancer; 2019 Feb; 19(1):176. PubMed ID: 30808421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis.
    Zhang Y; Zhao J; Ding M; Su Y; Cui D; Jiang C; Zhao S; Jia G; Wang X; Ruan Y; Jing Y; Xia S; Han B
    J Exp Clin Cancer Res; 2020 Dec; 39(1):282. PubMed ID: 33317606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.
    Huang G; Zhang H; Shi H; Zhang W; Wang T; Wang Z; Chen Q; Lian B; Li J; Yang G
    World J Surg Oncol; 2022 Dec; 20(1):407. PubMed ID: 36572885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
    Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
    Int J Pharm; 2018 Aug; 547(1-2):611-620. PubMed ID: 29933059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
    Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
    Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tea polyphenol-engineered hybrid cellular nanovesicles for cancer immunotherapy and androgen deprivation therapy.
    Guo Y; Wu J; Chen L; Liu L; Bi T; Pan Y; Meng QF; Wang C; Rao L; Li Q
    J Nanobiotechnology; 2024 Apr; 22(1):192. PubMed ID: 38637848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restoration of immunocyte functions by thymosin alpha1 in cyclophosphamide-induced immunodeficient mice.
    Ohmori H; Kamo M; Yamakoshi K; Nitta MH; Hikida M; Kanayama N
    Immunopharmacol Immunotoxicol; 2001 Feb; 23(1):75-82. PubMed ID: 11322651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 Expression and CD8
    Petitprez F; Fossati N; Vano Y; Freschi M; Becht E; Lucianò R; Calderaro J; Guédet T; Lacroix L; Rancoita PMV; Montorsi F; Fridman WH; Sautès-Fridman C; Briganti A; Doglioni C; Bellone M
    Eur Urol Focus; 2019 Mar; 5(2):192-196. PubMed ID: 28753812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer.
    Zheng Y; Wang PP; Fu Y; Chen YY; Ding ZY
    Int Immunopharmacol; 2022 Sep; 110():109030. PubMed ID: 35978519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt/β-catenin pathway.
    Lv J; Chen FK; Liu C; Liu PJ; Feng ZP; Jia L; Yang ZX; Hou F; Deng ZY
    Life Sci; 2020 Sep; 256():117925. PubMed ID: 32522570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life.
    Wang F; Yu T; Zheng H; Lao X
    Sci Rep; 2018 Aug; 8(1):12351. PubMed ID: 30120362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
    Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
    Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thymosin α1 protects from CTLA-4 intestinal immunopathology.
    Renga G; Bellet MM; Pariano M; Gargaro M; Stincardini C; D'Onofrio F; Mosci P; Brancorsini S; Bartoli A; Goldstein AL; Garaci E; Romani L; Costantini C
    Life Sci Alliance; 2020 Oct; 3(10):. PubMed ID: 32817121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression, purification and characterization of a novel soluble human thymosin alpha1 concatemer exhibited a stronger stimulation on mice lymphocytes proliferation and higher anti-tumor activity.
    Li W; Song L; Wu S; Xue X; Zhang L; He L; Han W; Wang Q; Ling R; Zhang W; Yan Z; Zhang Y
    Int J Biol Sci; 2011; 7(5):618-28. PubMed ID: 21647330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune modulation of CD4
    Liu H; Wang SH; Chen SC; Chen CY; Lo JL; Lin TM
    BMC Immunol; 2016 Nov; 17(1):45. PubMed ID: 27887569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.